

**Tuesday, August 29<sup>th</sup>, 2023, 12.45-13.45, Hall Pincus**

**New perspectives in PKU management - The change we can see**

*Chair: Cary Harding (Portland, OR, United States)*

Welcome & introduction

*Cary Harding (Portland, OR, United States)*

Behind the science: My PALYNZIQ® ▼ experience

*Cary Harding (Portland, OR, United States)*

Tackling barriers: Journey of a centre with a single specialist to deliver PALYNZIQ®

*Johannes Krämer (Ulm, Germany)*

From practice to evidence: The real-world impact of PALYNZIQ®

*Frank Rutsch (Münster, Germany)*

Q&A

*Faculty & audience*

▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. Healthcare professionals should report adverse events in accordance with their local requirements. Adverse events should also be reported to BioMarin on + 1 415 506 6179 or [drugsafety@bmrn.com](mailto:drugsafety@bmrn.com).

PALYNZIQ® (pegvaliase) is indicated for the treatment of patients with PKU aged 16 years and older who have inadequate blood phenylalanine control (blood phenylalanine levels greater than 600 µmol/L) despite prior management with available treatment options.

This will contain information on PALYNZIQ® which is not licensed in Israel, but is licensed in the European Union. Refer to your local Prescribing Information prior to using PALYNZIQ®.

This symposium is intended for Healthcare Professionals registered for SSIEM 2023.

This symposium is sponsored and funded by

**B:OMARIN®**